KR102444140B1 - 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법 - Google Patents

장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법 Download PDF

Info

Publication number
KR102444140B1
KR102444140B1 KR1020217030424A KR20217030424A KR102444140B1 KR 102444140 B1 KR102444140 B1 KR 102444140B1 KR 1020217030424 A KR1020217030424 A KR 1020217030424A KR 20217030424 A KR20217030424 A KR 20217030424A KR 102444140 B1 KR102444140 B1 KR 102444140B1
Authority
KR
South Korea
Prior art keywords
ctp
another embodiment
leu
ser
growth hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217030424A
Other languages
English (en)
Korean (ko)
Other versions
KR20210118490A (ko
Inventor
푸어드 페어스
우디 이얄 피마
Original Assignee
옵코 바이오로직스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/059,134 external-priority patent/US20140113860A1/en
Priority claimed from US14/309,496 external-priority patent/US20150038413A1/en
Application filed by 옵코 바이오로직스 리미티드 filed Critical 옵코 바이오로직스 리미티드
Priority to KR1020227031563A priority Critical patent/KR20220130254A/ko
Publication of KR20210118490A publication Critical patent/KR20210118490A/ko
Application granted granted Critical
Publication of KR102444140B1 publication Critical patent/KR102444140B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
KR1020217030424A 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법 Active KR102444140B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227031563A KR20220130254A (ko) 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14/059,134 2013-10-21
US14/059,134 US20140113860A1 (en) 2006-02-03 2013-10-21 Long-acting polypeptides and methods of producing and administering same
US14/309,496 US20150038413A1 (en) 2006-02-03 2014-06-19 Long-acting polypeptides and methods of producing and administering same
US14/309,496 2014-06-19
PCT/IL2014/050910 WO2015059695A1 (en) 2013-10-21 2014-10-21 Long-acting polypeptides and methods of producing and administering same
KR1020167013555A KR20160068969A (ko) 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167013555A Division KR20160068969A (ko) 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227031563A Division KR20220130254A (ko) 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법

Publications (2)

Publication Number Publication Date
KR20210118490A KR20210118490A (ko) 2021-09-30
KR102444140B1 true KR102444140B1 (ko) 2022-09-15

Family

ID=52992360

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217030424A Active KR102444140B1 (ko) 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법
KR1020167013555A Ceased KR20160068969A (ko) 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법
KR1020227031563A Ceased KR20220130254A (ko) 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법
KR1020247021540A Ceased KR20240110069A (ko) 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020167013555A Ceased KR20160068969A (ko) 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법
KR1020227031563A Ceased KR20220130254A (ko) 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법
KR1020247021540A Ceased KR20240110069A (ko) 2013-10-21 2014-10-21 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법

Country Status (21)

Country Link
EP (2) EP3060239B1 (OSRAM)
JP (3) JP6640720B2 (OSRAM)
KR (4) KR102444140B1 (OSRAM)
CN (1) CN106163543A (OSRAM)
AU (3) AU2014338575B2 (OSRAM)
CA (1) CA2928269C (OSRAM)
DK (1) DK3060239T3 (OSRAM)
ES (1) ES2811068T3 (OSRAM)
FR (1) FR22C1035I2 (OSRAM)
HR (1) HRP20201114T1 (OSRAM)
HU (2) HUE050002T2 (OSRAM)
IL (1) IL297219B2 (OSRAM)
LU (1) LUC00259I2 (OSRAM)
MX (2) MX381148B (OSRAM)
NL (1) NL301170I2 (OSRAM)
PL (1) PL3060239T3 (OSRAM)
PT (1) PT3060239T (OSRAM)
RU (1) RU2746943C2 (OSRAM)
SI (1) SI3060239T1 (OSRAM)
TW (5) TWI777407B (OSRAM)
WO (1) WO2015059695A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201114T1 (hr) 2013-10-21 2020-10-30 Opko Biologics Ltd. Dugodjelujući polipeptidi i postupci njihove proizvodnje i primjene
JOP20190019A1 (ar) * 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
CN109942717A (zh) * 2019-04-24 2019-06-28 上海延立药业有限公司 一种长效重组人促卵泡激素及其制备方法和应用
WO2022197961A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Methods of administering long-acting growth hormone polypeptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013018098A2 (en) 2011-08-02 2013-02-07 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
EP0264166B1 (en) 1986-04-09 1996-08-21 Genzyme Corporation Transgenic animals secreting desired proteins into milk
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
ATE110571T1 (de) 1988-05-06 1994-09-15 Toray Industries Stabile interferon-beta-zusammensetzung.
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
EP0461200B1 (en) 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8946155B2 (en) * 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
DE102007006189B4 (de) * 2007-02-07 2009-07-30 Isotopen Technologien München AG Vorrichtung zum Befüllen eines medizinischen Instruments mit einer radioaktiven Substanz und Verfahren
HRP20201114T1 (hr) 2013-10-21 2020-10-30 Opko Biologics Ltd. Dugodjelujući polipeptidi i postupci njihove proizvodnje i primjene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013018098A2 (en) 2011-08-02 2013-02-07 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same

Also Published As

Publication number Publication date
FR22C1035I1 (fr) 2022-09-09
AU2022246472B2 (en) 2025-08-14
SI3060239T1 (sl) 2020-10-30
TWI777407B (zh) 2022-09-11
TW201536327A (zh) 2015-10-01
MX2021003908A (es) 2021-06-23
MX381148B (es) 2025-03-12
JP7445695B2 (ja) 2024-03-07
EP3060239A1 (en) 2016-08-31
ES2811068T3 (es) 2021-03-10
JP2020073541A (ja) 2020-05-14
KR20240110069A (ko) 2024-07-12
TWI893324B (zh) 2025-08-11
JP2022088521A (ja) 2022-06-14
RU2021110927A3 (OSRAM) 2021-12-08
RU2016119565A (ru) 2018-11-02
CA2928269C (en) 2023-03-14
HUE050002T2 (hu) 2020-11-30
MX2016005227A (es) 2016-08-12
LUC00259I2 (OSRAM) 2025-04-25
JP2016535015A (ja) 2016-11-10
IL297219A (en) 2022-12-01
EP3763733A1 (en) 2021-01-13
CA2928269A1 (en) 2015-04-30
IL297219B1 (en) 2023-10-01
KR20210118490A (ko) 2021-09-30
FR22C1035I2 (fr) 2024-02-16
PL3060239T3 (pl) 2020-11-02
JP7051797B2 (ja) 2022-04-11
TW202120120A (zh) 2021-06-01
AU2014338575A1 (en) 2016-06-02
CN106163543A (zh) 2016-11-23
WO2015059695A1 (en) 2015-04-30
NL301170I2 (nl) 2022-06-16
TW201536313A (zh) 2015-10-01
AU2020200874A1 (en) 2020-02-27
RU2016119565A3 (OSRAM) 2019-01-22
DK3060239T3 (da) 2020-08-03
HUS2200014I1 (hu) 2022-05-28
EP3060239B1 (en) 2020-05-13
PT3060239T (pt) 2020-08-26
RU2746943C2 (ru) 2021-04-22
NL301170I1 (nl) 2022-04-29
AU2014338575B2 (en) 2019-11-07
TW201536312A (zh) 2015-10-01
TWI720940B (zh) 2021-03-11
AU2022246472A1 (en) 2022-11-10
TW202317176A (zh) 2023-05-01
HRP20201114T1 (hr) 2020-10-30
RU2021110927A (ru) 2021-05-21
KR20160068969A (ko) 2016-06-15
EP3060239A4 (en) 2017-05-31
TWI720939B (zh) 2021-03-11
IL297219B2 (en) 2024-02-01
KR20220130254A (ko) 2022-09-26
JP6640720B2 (ja) 2020-02-05

Similar Documents

Publication Publication Date Title
US12029780B2 (en) Long-acting polypeptides and methods of producing and administering same
EP2739298B1 (en) Long-acting growth hormone and methods of producing same
US8304386B2 (en) Long-acting growth hormone and methods of producing same
US20200131242A1 (en) Methods of treatment with long-acting hormone
AU2022246472A1 (en) Long-acting polypeptides and methods of producing and administering same
HK40034109A (en) Long-acting polypeptides and methods of producing and administering same
RU2798845C2 (ru) Полипептиды длительного действия и способы их получения и введения
HK40008897A (en) Long-acting growth hormone and methods of producing same
HK40008897B (en) Long-acting growth hormone and methods of producing same
US20150126444A1 (en) Long-acting polypeptides and methods of producing and administering same
BR122020000943B1 (pt) Formulação farmacêutica, processo para preparação e enchimento de seringa com a mesma
BR112016008950B1 (pt) Uso de um polipeptídeo modificado com peptídeo carboxi terminal (ctp) de gonadotropina coriônica
HK1230924A1 (en) Long-acting polypeptides and methods of producing and administering same

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210923

Application number text: 1020167013555

Filing date: 20160523

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211129

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220614

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220913

Application number text: 1020167013555

Filing date: 20160523

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220913

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220913

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250625

Start annual number: 4

End annual number: 4